Back to search results

Phase III Study of Rilvegostomig for Liver Cancer

This study is testing different combinations of medicines for advanced hepatocellular carcinoma (HCC), a type of liver cancer. Researchers want to see if rilvegostomig, given with bevacizumab (Avastin) and possibly tremelimumab, works better than atezolizumab (Tecentriq) with bevacizumab. All these medicines are given through an IV. You might be able to join if you have advanced HCC that can't be cured by surgery or other local treatments, have a good general health status (WHO/ECOG 0 or 1), and a Child-Pugh Score of A. The main goal is to see how long people live with these treatments. The study plans to enroll 1220 people.

Study design
This is a Phase III, randomized study with three groups, comparing different drug combinations. It is open-label, meaning you and your doctor will know which treatment you are receiving, but the sponsor will not.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your health will be monitored for up to approximately 6 years to assess how long you live after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06921785

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Recruiting
PHASE3Ages 18+InterventionalTreatment
AstraZeneca
~1,220 participants
Updated 2026-09-03 on ClinicalTrials.gov
What's tested:TremelimumabRilvegostomigBevacizumabAtezolizumab

At a glance

Recruiting sites
180 of 219 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To demonstrate the efficacy of Arm A relative to Arm C by assessment of OS in participants with advanced HCC
Measured over Up to approximately 6 years

Conditions

Hepatocellular Carcinoma

Explore related trials

Hepatocellular Carcinoma

NCT06921785

Where you'd take part

This study runs at 219 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Research Site

    Phoenix, Arizonano site contact published

    Recruiting

  • Research Site

    Tucson, Arizonano site contact published

    Recruiting

  • Research Site

    Los Angeles, Californiano site contact published

    Recruiting

  • Research Site

    Palo Alto, Californiano site contact published

    Recruiting

  • Research Site

    New Haven, Connecticutno site contact published

    Recruiting

  • Research Site

    Newark, Delawareno site contact published

    Recruiting

  • Research Site

    Jacksonville, Floridano site contact published

    Recruiting

  • Research Site

    Orlando, Floridano site contact published

    Not yet recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

AstraZeneca Clinical Study Information Center
[email protected]
1-877-240-9479
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Locally advanced or metastatic and/or unresectable HCC
WHO/ECOG performance status of 0 or 1
BCLC stage B (that is not eligible for locoregional therapy) or stage C.
Child-Pugh Score class A
At least one measurable target lesion
Participants with active HBV infection must receive antiviral therapy for a minimum of 14 days prior to randomization to show evidence of HBV stabilization or signs of viral response.
Participants with active HCV infection must be well controlled. Participants co-infected with HBV and HCV are not eligible.
Adequate organ and bone marrow function measured during the screening period.
Adequate organ and bone marrow function measured during the screening period
Must not have received prior systemic therapy for intermediate, advanced, or metastatic HCC.
Disease that is not amenable to curative surgical and/or locoregional therapies. For participants who received locoregional therapy for HCC, locoregional therapy must have been completed ≥ 28 days prior to the baseline scan for the current study.

Exclusion

Any evidence of uncontrolled intercurrent diseases
Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment
History of another primary malignancy
Persistent toxicities caused by previous anti-cancer therapy excluding alopecia, not yet improved to Grade ≤ 1 or baseline.
Clinically meaningful ascites, pleural effusion, or pericardial effusion requiring non-pharmacologic intervention to maintain symptomatic control within 6 months prior to the first scheduled dose.
History of active primary immunodeficiency or active infection
History of hepatic encephalopathy
Current or recent (within 10 days of first dose of study treatment) use of aspirin (≥ 325 mg/day) or treatment with dipyridamole, ticlopidine, clopidogrel, and cilostazol
Current or recent (within 10 days prior to study treatment start) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purposes is ineligible
History of significant bleeding disorders, vasculitis, or a significant bleeding episode from the GI tract within 6 months prior to study randomization.
Participants with untreated or incompletely treated varices with bleeding or high-risk (red wale signs or other high-risk factors) for bleeding.
Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
Central nervous system metastases or spinal cord compression (including asymptomatic and adequately treated disease)
Prior treatment with anti-CTLA-4 and/or anti-TIGIT.
Radiotherapy within 28 days and abdominal/ pelvic radiotherapy within 60 days prior to initiation of study treatment, except palliative radiotherapy to bone lesions within 7 days prior to initiation of study treatment

What this trial measures

  • To demonstrate the efficacy of Arm A relative to Arm C by assessment of OS in participants with advanced HCCUp to approximately 6 years

    OS is defined as the time from randomisation until the date of death due to any cause.